These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 21375166)
61. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716 [TBL] [Abstract][Full Text] [Related]
62. Thin strut chrome-cobalt stent implantation for treatment of de-novo lesions in small coronary vessels: results of the RISICO Italian Registry (Registro Italiano Mini VISION nei piccolo Vasi) utilizing the Mini VISION coronary stent platform. Brambilla N; Morici N; Bedogni F; De Benedictis M; Scrocca I; Naldi M; Fiscella A; Prosperi F; Dominici M; Rebuzzi A; Colombo A; Sangiorgi GM; J Cardiovasc Med (Hagerstown); 2009 Nov; 10(11):852-8. PubMed ID: 19550353 [TBL] [Abstract][Full Text] [Related]
63. Paclitaxel-coated balloon angioplasty for de novo coronary lesions: a long-term follow-up study. Benezet J; Gutiérrez-Barrios A; Agarrado A; Gamaza S; Ruiz-Fernández D; Del Río A; Oneto J Minerva Cardioangiol; 2016 Feb; 64(1):15-22. PubMed ID: 26989946 [TBL] [Abstract][Full Text] [Related]
66. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW; JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715 [TBL] [Abstract][Full Text] [Related]
67. Long-term clinical follow-up after drug-eluting stent implantation for bare metal in-stent restenosis. Berta B; Ruzsa Z; Barczi G; Becker D; Geller L; Jambrik Z; Molnar L; Szabo G; Merkely B J Interv Cardiol; 2013 Jun; 26(3):271-7. PubMed ID: 23586796 [TBL] [Abstract][Full Text] [Related]
68. 3-year follow-up of 100 consecutive coronary bifurcation lesions treated with Taxus stents and the crush technique. Chue CD; Routledge HC; Ludman PF; Townend JN; Epstein AC; Buller NP; Doshi SN Catheter Cardiovasc Interv; 2010 Mar; 75(4):605-13. PubMed ID: 20066725 [TBL] [Abstract][Full Text] [Related]
69. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553 [TBL] [Abstract][Full Text] [Related]
70. The effect of stent coating on stent deliverability: direct randomised comparison of drug eluting and bare metal stents using the same stent platform. Siminiak T; Link R; Wołoszyn M; Kałmucki P; Baszko A Kardiol Pol; 2012; 70(10):998-1002. PubMed ID: 23080088 [TBL] [Abstract][Full Text] [Related]
71. Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial. Costa RA; Abizaid A; Abizaid AS; Garcia del Blanco B; Berland J; Petrov I; Brenot P; van Guens RJ; Royer T; Rubino P; Lesiak M; Fajadet J; EuroIntervention; 2012 Mar; 7(11):1301-9. PubMed ID: 22433193 [TBL] [Abstract][Full Text] [Related]
72. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443 [TBL] [Abstract][Full Text] [Related]
73. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. Naganuma T; Latib A; Sgueglia GA; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Panoulas VF; Buffoli F; Tamburino C; Varbella F; Colombo A Int J Cardiol; 2015 Apr; 184():17-21. PubMed ID: 25705005 [TBL] [Abstract][Full Text] [Related]
74. Drug-Eluting Balloon for Management of Coronary In-Stent Restenosis in a South Asian Population: Experience From a Tertiary-Care Hospital in Pakistan. Ahmed SW; Hussain B; Ahmed B; Rahman N; Ali J; Faheem O J Invasive Cardiol; 2021 Feb; 33(2):E127-E134. PubMed ID: 33279879 [TBL] [Abstract][Full Text] [Related]
75. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436 [TBL] [Abstract][Full Text] [Related]
76. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents. Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J; J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863 [TBL] [Abstract][Full Text] [Related]
77. Association between tissue characteristics evaluated with optical coherence tomography and mid-term results after paclitaxel-coated balloon dilatation for in-stent restenosis lesions: a comparison with plain old balloon angioplasty. Tada T; Kadota K; Hosogi S; Miyake K; Amano H; Nakamura M; Izawa Y; Kubo S; Ichinohe T; Hyoudou Y; Eguchi H; Hayakawa Y; Otsuru S; Hasegawa D; Shigemoto Y; Habara S; Tanaka H; Fuku Y; Kato H; Goto T; Mitsudo K Eur Heart J Cardiovasc Imaging; 2014 Mar; 15(3):307-15. PubMed ID: 24042176 [TBL] [Abstract][Full Text] [Related]
78. A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry. Agostoni P; Foley D; Lesiak M; Belkacemi A; Dens J; Kumsars I; Scott B; Oemrawsingh P; Dubois C; Garcia E; Lefèvre T; Stella PR EuroIntervention; 2012 Mar; 7(11):1293-300. PubMed ID: 22433192 [TBL] [Abstract][Full Text] [Related]
79. Comparison of drug-eluting balloon versus drug-eluting stent for treatment of coronary artery disease: a meta-analysis of randomized controlled trials. Liu L; Liu B; Ren J; Hui G; Qi C; Wang J BMC Cardiovasc Disord; 2018 Mar; 18(1):46. PubMed ID: 29499651 [TBL] [Abstract][Full Text] [Related]
80. Long-term follow-up after sirolimus-coated balloon use for coronary artery disease. Final results of the Nanolutè study. El-Mokdad R; di Palma G; Cortese B Catheter Cardiovasc Interv; 2020 Nov; 96(5):E496-E500. PubMed ID: 32191384 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]